Johns Hopkins Leads $24M Multinational Consortium to Find Hepatitis B Cure

Why It Matters

With 300 million chronic carriers worldwide, a functional hepatitis B cure could dramatically cut liver‑related mortality and transform treatment for HIV‑co‑infected patients.

Key Takeaways

• 5-year, $24M NIH grant
• 675 participants enrolled first year
• Multi‑site cohort spans five continents
• Seven specialized cores generate biomarkers and data
• Focus on functional cure and investigator training

Pulse Analysis

Hepatitis B remains one of the world’s most persistent viral threats, with roughly 300 million chronic carriers and an annual influx of over a million new infections. Although a safe birth‑dose vaccine exists, gaps in delivery—particularly across the Western Pacific and sub‑Saharan Africa—keep mortality from cirrhosis and liver cancer alarmingly high. In response, the National Institute of Allergy and Infectious Diseases has awarded a five‑year, $24 million grant to a multinational Hepatitis B and HIV Cure Consortium led by Johns Hopkins Medicine. The initiative unites research teams from the United States, Brazil, India, Senegal and Uganda, creating a global platform to accelerate cure‑focused science.

The consortium’s operational model hinges on seven interlocking cores that translate laboratory discoveries into patient‑centric outcomes. A Virology Core will develop sensitive HBV replication biomarkers, while a Multiomics Core applies next‑generation sequencing and proteomics to map viral‑host interactions. A Shared Resources Core curates a repository of blood, liver tissue and peripheral blood mononuclear cells drawn from an initial cohort of 450 HIV‑HBV co‑infected and 225 HBV‑only participants. Clinical, Immunology and Translational projects leverage these specimens to dissect viral dynamics, immune responses, and treatment‑induced antigen loss, all coordinated by a Biostats/Data Core.

By integrating biomarker data with mechanistic modeling, the consortium aims to define a functional cure—sustained loss of hepatitis B surface antigen without lifelong therapy. Success would reshape global health policy, reduce the economic burden of chronic liver disease, and open new markets for curative therapeutics. Moreover, the program’s emphasis on training early‑stage investigators and building capacity at partner sites promises a lasting research pipeline, especially critical for regions where HBV and HIV co‑infection rates are highest. The collaborative framework therefore positions Johns Hopkins and its partners at the forefront of next‑generation antiviral innovation.